INNATE PHARMA SP.ADR/1 (IDDA) - Net Assets
Based on the latest financial reports, INNATE PHARMA SP.ADR/1 (IDDA) has net assets worth €-21.70 Million EUR (≈ $-25.37 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€62.72 Million ≈ $73.33 Million USD) and total liabilities (€84.42 Million ≈ $98.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check INNATE PHARMA SP.ADR/1 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-21.70 Million |
| % of Total Assets | -34.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 132.93 |
INNATE PHARMA SP.ADR/1 - Net Assets Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's net assets have evolved over time, based on quarterly financial data. Also explore IDDA total asset value for the complete picture of this company's asset base.
Annual Net Assets for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below shows the annual net assets of INNATE PHARMA SP.ADR/1 from 2021 to 2025. For live valuation and market cap data, see INNATE PHARMA SP.ADR/1 market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-21.70 Million ≈ $-25.37 Million |
-345.69% |
| 2024-12-31 | €8.83 Million ≈ $10.33 Million |
-82.98% |
| 2023-12-31 | €51.90 Million ≈ $60.68 Million |
-4.16% |
| 2022-12-31 | €54.15 Million ≈ $63.31 Million |
-49.60% |
| 2021-12-31 | €107.44 Million ≈ $125.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to INNATE PHARMA SP.ADR/1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16332900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €413.84 Million | % |
| Total Equity | €-21.70 Million | 100.00% |
INNATE PHARMA SP.ADR/1 Competitors by Market Cap
The table below lists competitors of INNATE PHARMA SP.ADR/1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lang Inc
TW:6165
|
$116.20 Million |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
$116.21 Million |
|
ELK-Desa Resources Bhd
KLSE:5228
|
$116.22 Million |
|
Tat Gida Sanayi AS
IS:TATGD
|
$116.24 Million |
|
Leap Therapeutics Inc
NASDAQ:LPTX
|
$116.14 Million |
|
KOMPLETT ASA NK -40
F:GJ60
|
$116.08 Million |
|
Energoaqua a.s.
PR:ENRGA
|
$116.05 Million |
|
Nelly Group AB
ST:NELLY
|
$116.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INNATE PHARMA SP.ADR/1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,834,000 to -21,704,000, a change of -30,538,000 (-345.7%).
- Net loss of 49,177,000 reduced equity.
- Other factors increased equity by 18,639,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-49.18 Million | -226.58% |
| Other Changes | €18.64 Million | +85.88% |
| Total Change | €- | -345.69% |
Book Value vs Market Value Analysis
This analysis compares INNATE PHARMA SP.ADR/1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.35 | €1.06 | x |
| 2022-12-31 | €0.68 | €1.06 | x |
| 2023-12-31 | €0.64 | €1.06 | x |
| 2024-12-31 | €0.11 | €1.06 | x |
| 2025-12-31 | €-0.23 | €1.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INNATE PHARMA SP.ADR/1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1764.51%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-146.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -49.15% | -436.08% | 0.05x | 2.49x | €-63.55 Million |
| 2022 | -107.30% | -117.19% | 0.25x | 3.68x | €-63.52 Million |
| 2023 | -14.59% | -14.59% | 0.30x | 3.38x | €-12.76 Million |
| 2024 | -560.01% | -391.97% | 0.11x | 12.57x | €-50.35 Million |
| 2025 | 0.00% | -1764.51% | 0.04x | 0.00x | €-47.01 Million |
Industry Comparison
This section compares INNATE PHARMA SP.ADR/1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INNATE PHARMA SP.ADR/1 (IDDA) | €-21.70 Million | -49.15% | N/A | $116.15 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more